Intrinsic Antiviral Factors 2022

A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Viral Immunology, Vaccines, and Antivirals".

Deadline for manuscript submissions: closed (31 January 2023) | Viewed by 3776

Special Issue Editor


E-Mail Website
Guest Editor
Laboratory of Viral Trafficking, Restriction and Innate Signaling, Institut de Recherche en Infectiologie de Montpellier (IRIM), 1919 Route de Mende, 34090 Montpellier, France
Interests: antiviral innate immunity; interferon response; restriction factors; TRIM proteins; virus-host interactions
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cells possess all the essential factors and machineries that viruses need to achieve their replication and are therefore the victims of perpetual hostile takeovers from these parasites. This continuous selective pressure they have been exposed to for millions of years has led eukaryotic cells to develop specific factors that are dedicated to antiviral defenses. These intrinsic defenses are now considered as the third arm of immunity, in addition to the traditionally bipartite immune system of innate and adaptive immunity. This notion of intrinsic immunity emerged more than 10 years ago, following the identification of cellular factors that interfere with retroviral replication, the so-called restriction factors. Since the discovery of the prototype antiretroviral restriction factors Fv1, APOBEC3G, and TRIM5a, a plethora of other intrinsic antiviral factors have been identified and interfere with the replication of many different viruses. Although they can be constitutively expressed in given cell types and thus block replication directly, most intrinsic antiviral factors are induced by interferons to amplify their antiviral activity.

Cells have thus recently emerged as new battlefields where virus and host confrontations can be witnessed first-hand, since viruses have to either escape or counteract these intracellular barriers in order to achieve their replication and ensure their propagation.

This Special Issue is intended to provide an up-to-date view of the numerous intrinsic antiviral factors that have been or are yet to be identified and the various strategies developed by viruses to evade these factors.

Dr. Sébastien Nisole
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • restriction factors
  • antiviral proteins
  • intrinsic immunity
  • host defense
  • antiviral ISGs
  • virus-cell interactions

Related Special Issue

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 2536 KiB  
Article
Isoforms of Human MARCH1 Differ in Ability to Restrict Influenza A Viruses Due to Differences in Their N Terminal Cytoplasmic Domain
by Fernando Villalón-Letelier, Rubaiyea Farrukee, Sarah L. Londrigan, Andrew G. Brooks and Patrick C. Reading
Viruses 2022, 14(11), 2549; https://0-doi-org.brum.beds.ac.uk/10.3390/v14112549 - 18 Nov 2022
Cited by 5 | Viewed by 1783
Abstract
MARCH1 and MARCH8 are closely related E3 ubiquitin ligases that ubiquitinate an overlapping spectrum of host proteins and restrict replication of certain viruses. While the antiviral activity of MARCH8 has been intensively studied, less is known regarding virus inhibition by MARCH1. Isoforms 1 [...] Read more.
MARCH1 and MARCH8 are closely related E3 ubiquitin ligases that ubiquitinate an overlapping spectrum of host proteins and restrict replication of certain viruses. While the antiviral activity of MARCH8 has been intensively studied, less is known regarding virus inhibition by MARCH1. Isoforms 1 and 2 of MARCH1 are very similar in overall structure but show major differences in their N-terminal cytoplasmic domain (N-CT). Herein, we used a doxycycline-inducible overexpression system to demonstrate that MARCH1.1 reduces titres of influenza A virus (IAV) released from infected cells whereas MARCH1.2 does not. The deletion of the entire N-CT of MARCH1.2 restored its ability to restrict IAV infectivity and sequential deletions mapped the restoration of IAV inhibition to delete the 16 N-terminal residues within the N-CT of MARCH1.2. While only MARCH1.1 mediated anti-IAV activity, qPCR demonstrated the preferential expression of MARCH1.2 over MARCH1.1 mRNA in unstimulated human peripheral blood mononuclear cells and also in monocyte-derived macrophages. Together, these studies describe the differential ability of MARCH1 isoforms to restrict IAV infectivity for the first time. Moreover, as published immunological, virological and biochemical studies examining the ability of MARCH1 to target particular ligands generally use only one of the two isoforms, these findings have broader implications for our understanding of how MARCH1 isoforms might differ in their ability to modulate particular host and/or viral proteins. Full article
(This article belongs to the Special Issue Intrinsic Antiviral Factors 2022)
Show Figures

Figure 1

Review

Jump to: Research

15 pages, 1610 KiB  
Review
LAG-3 Contribution to T Cell Downmodulation during Acute Respiratory Viral Infections
by Linmar Rodríguez-Guilarte, Mario A. Ramírez, Catalina A. Andrade and Alexis M. Kalergis
Viruses 2023, 15(1), 147; https://0-doi-org.brum.beds.ac.uk/10.3390/v15010147 - 03 Jan 2023
Cited by 2 | Viewed by 1529
Abstract
LAG-3 is a type I transmembrane protein expressed on immune cells, such as activated T cells, and binds to MHC class II with high affinity. LAG-3 is an inhibitory receptor, and its multiple biological activities on T cell activation and effector functions play [...] Read more.
LAG-3 is a type I transmembrane protein expressed on immune cells, such as activated T cells, and binds to MHC class II with high affinity. LAG-3 is an inhibitory receptor, and its multiple biological activities on T cell activation and effector functions play a regulatory role in the immune response. Immunotherapies directed at immune checkpoints, including LAG-3, have become a promising strategy for controlling malignant tumors and chronic viral diseases. Several studies have suggested an association between the expression of LAG-3 with an inadequate immune response during respiratory viral infections and the susceptibility to reinfections, which might be a consequence of the inhibition of T cell effector functions. However, important information relative to therapeutic potential during acute viral lower respiratory tract infections and the mechanism of action of the LAG-3 checkpoint remains to be characterized. In this article, we discuss the contribution of LAG-3 to the impairment of T cells during viral respiratory infections. Understanding the host immune response to respiratory infections is crucial for developing effective vaccines and therapies. Full article
(This article belongs to the Special Issue Intrinsic Antiviral Factors 2022)
Show Figures

Figure 1

Back to TopTop